Purpose: To compare the performance of two different spectral-domain optical coherence tomography angiography (OCTA) devices in clinical practice by evaluating examination execution time and the number of motion artifacts per image. Methods: Seventy-six patients affected by different ocular diseases and 13 healthy subjects consecutively underwent assessments by two different OCTA devices: AngioPlex (Zeiss Meditec, Inc., Dublin, Calif., USA) and AngioVue (OptoVue, Inc., Fremont, Calif., USA). Two different operators (L.A.D.V. and L.B.) measured execution times, excluded low-quality images, and counted the number of motion artifacts per image. Results: The mean execution time was shorter with AngioPlex than with AngioVue for all subjects (3 min 32 s ± 1 min 45 s vs. 4 min 35 s ± 1 min 11 s; p < 0.0001), for the healthy subjects (2 min 31 s ± 45 s vs. 4 min 1 s ± 53 s; p = 0.003), and for the patients (3 min 44 s ± 1 min 48 s vs. 4 min 42 s ± 1 min 13 s; p < 0.0001). The percentages of available images, low-signal-strength images, and images impossible to analyze of the total acquired images obtained using AngioPlex or AngioVue were 85, 6, and 9% and 56, 29, and 15%, respectively. The mean number of motion artifacts was significantly lower in images obtained using AngioPlex than in images obtained using AngioVue for all patients (6.5 ± 5.9 vs. 12.6 ± 8.5; p < 0.0001), for the healthy subjects (6.5 ± 4.6 vs. 10.9 ± 7.9; p = 0.0009), and for the patients (6.6 ± 6.3 vs. 13.1 ± 8.7; p < 0.0001). There was no correlation between the number of artifacts and execution time or patients' age. Conclusion: AngioPlex and AngioVue are useful devices in clinical practice. AngioPlex requires a shorter execution time and provides a higher number of images available for analysis with fewer motion artifacts.

Keywords:
AVANTI™, Eye-tracking, Execution time, Spectral-domain optical coherence tomography, AngioPlex, CIRRUS™, AngioVue, Optical coherence tomography angiography, Macula, Motion artifacts
1.
Fingler J, Readhead C, Schwartz DM, Fraser SE: Phase-contrast OCT imaging of transverse flows in the mouse retina and choroid. Invest Ophthalmol Vis Sci 2008;49:5055-5059.
2.
Fingler J, Schwartz D, Yang C, Fraser SE: Mobility and transverse flow visualization using phase variance contrast with spectral domain optical coherence tomography. Opt Express 2007;15:12636-12653.
3.
Mariampillai A, Standish BA, Moriyama EH, Khurana M, Munce NR, Leung MK, Jiang J, Cable A, Wilson BC, Vitkin IA, Yang VX: Speckle variance detection of microvasculature using swept-source optical coherence tomography. Opt Lett 2008;33:1530-1532.
4.
Mariampillai A, Leung MK, Jarvi M, Standish BA, Lee K, Wilson BC, Vitkin A, Yang VX: Optimized speckle variance OCT imaging of microvasculature. Opt Lett 2010;35:1257-1259.
5.
Kim DY, Fingler J, Werner JS, Schwartz DM, Fraser SE, Zawadzki RJ: In vivo volumetric imaging of human retinal circulation with phase-variance optical coherence tomography. Biomed Opt Express 2011;2:1504-1513.
6.
An L, Shen TT, Wang RK: Using ultrahigh sensitive optical microangiography to achieve comprehensive depth resolved microvasculature mapping for human retina. J Biomed Opt 2011;16:106013.
7.
Mahmud MS, Cadotte DW, Vuong B, Sun C, Luk TW, Mariampillai A, Yang VX: Review of speckle and phase variance optical coherence tomography to visualize microvascular networks. J Biomed Opt 2013;18:50901.
8.
Spaide RF, Fujimoto JG, Waheed NK: Image artifacts in optical coherence tomography angiography. Retina 2015;35:2163-2180.
9.
Spaide RF, Klancnik JM Jr, Cooney MJ: Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography. JAMA Ophthalmol 2015;133:45-50.
10.
Zhang A, Zhang Q, Wang RK: Minimizing projection artifacts for accurate presentation of choroidal neovascularization in OCT micro-angiography. Biomed Opt Express 2015;6:4130-4143.
11.
Jia Y, Tan O, Tokayer J, Potsaid B, Wang Y, Liu JJ, Kraus MF, Subhash H, Fujimoto JG, Hornegger J, Huang D: Split-spectrum amplitude-decorrelation angiography with optical coherence tomography. Opt Express 2012;20:4710-4725.
12.
Huang D, Jia Y, Gao SS, Lumbroso B, Rispoli M: Optical coherence tomography angiography using the OptoVue device. Dev Ophthalmol 2016;56:6-12.
13.
Rosenfeld PJ, Durbin MK, Roisman L, Zheng F, Miller A, Robbins G, Schaal KB, Gregori G: Zeiss AngioPlex spectral domain optical coherence tomography angiography: technical aspects. Dev Ophthalmol 2016;56:18-29.
14.
Bandello F, Corbelli E, Carnevali A, Pierro L, Querques G: Optical coherence tomography angiography of diabetic retinopathy. Dev Ophthalmol 2016;56:107-112.
15.
Srour M, Querques G, Souied EH: Optical coherence tomography angiography of idiopathic polypoidal choroidal vasculopathy. Dev Ophthalmol 2016;56:71-76.
16.
Iafe NA, Phasukkijwatana N, Sarraf D: Optical coherence tomography angiography of type 1 neovascularization in age-related macular degeneration. Dev Ophthalmol 2016;56:45-51.
17.
Querques G, Miere A, Souied EH: Optical coherence tomography angiography features of type 3 neovascularization in age-related macular degeneration. Dev Ophthalmol 2016;56:57-61.
18.
Battaglia Parodi M, Pierro L, Gagliardi M, Lattanzio R, Querques G, Bandello F: Optical coherence tomography angiography in dystrophies. Dev Ophthalmol 2016;56:159-165.
19.
Querques G, Corvi F, Querques L, Souied EH, Bandello F: Optical coherence tomography angiography of choroidal neovascularization secondary to pathologic myopia. Dev Ophthalmol 2016;56:101-106.
20.
Waheed NK, Moult EM, Fujimoto JG, Rosenfeld PJ: Optical coherence tomography angiography of dry age-related macular degeneration. Dev Ophthalmol 2016;56:91-100.
21.
Souied EH, Miere A, Cohen SY, Semoun O, Querques G: Optical coherence tomography angiography of fibrosis in age-related macular degeneration. Dev Ophthalmol 2016;56:86-90.
22.
Pierro L, Battaglia Parodi M, Rabiolo A, Introini U, Querques G, Bandello F: Optical coherence tomography angiography of miscellaneous retinal disease. Dev Ophthalmol 2016;56:174-180.
23.
Baumal CR: Optical coherence tomography angiography of retinal artery occlusion. Dev Ophthalmol 2016;56:122-131.
24.
Novais EA, Waheed NK: Optical coherence tomography angiography of retinal vein occlusion. Dev Ophthalmol 2016;56:132-138.
25.
Souied EH, El Ameen A, Semoun O, Miere A, Querques G, Cohen SY: Optical coherence tomography angiography of type 2 neovascularization in age-related macular degeneration. Dev Ophthalmol 2016;56:52-56.
26.
Lumbroso B, Rispoli M, Savastano MC, Jia Y, Tan O, Huang D: Optical coherence tomography angiography study of choroidal neovascularization early response after treatment. Dev Ophthalmol 2016;56:77-85.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.